Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kiani, A.
Right arrow Articles by Engelhardt, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiani, A.
Right arrow Articles by Engelhardt, R.
Related Collections
Right arrow Phagocytes
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Downregulation of the Proinflammatory Cytokine Response to Endotoxin by Pretreatment With the Nontoxic Lipid A Analog SDZ MRL 953 in Cancer Patients

Alexander Kiani, Astrid Tschiersch, Elke Gaboriau, Florian Otto, Alexander Seiz, Hans-Peter Knopf, Peter Stütz, Lothar Färber, Ulrike Haus, Chris Galanos, Roland Mertelsmann, and Rupert Engelhardt

From the Division of Hematology/Oncology, Department of Internal Medicine I, University Hospital of Freiburg, Freiburg, Germany; the Sandoz Research Institute, Vienna, Austria; Sandoz Pharma Ltd, Nuremberg, Germany; and the Max Planck Institute for Immunobiology, Freiburg, Germany.

Interfering with the endotoxin-mediated cytokine cascade is thought to be a promising approach to prevent septic complications in gram-negative infections. The synthetic lipid A analog SDZ MRL 953 has been shown to be protective against endotoxic shock and bacterial infection in preclinical in vivo models. As part of a trial of unspecific immunostimulation in cancer patients, we conducted a double-blind, randomized, vehicle-controlled phase I trial of SDZ MRL 953 to investigate, first, its biologic effects and safety of administration in humans and, second, its influence on reactions to a subsequent challenge of endotoxin (Salmonella abortus equi). Twenty patients were treated intravenously with escalating doses of SDZ MRL 953 or vehicle control, followed by an intravenous application of endotoxin (2 ng/kg of body weight [BW]). Administration of SDZ MRL 953 was safe and well-tolerated. SDZ MRL 953 itself increased granulocyte counts and serum levels of granulocyte colony-stimulating factor (G-CSF ) and interleukin-6 (IL-6), but not of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha ), IL-1beta , and IL-8. Compared with vehicle control, pretreatment with SDZ MRL 953 markedly reduced the release of TNF-alpha , IL-1beta , IL-8, IL-6, and G-CSF, but augmented the increase in granulocyte counts to endotoxin. Induction of tolerance to the endotoxin-mediated cascade of proinflammatory cytokines by pretreatment with SDZ MRL 953 in patients at risk may help to prevent complications of gram-negative sepsis.

Blood, Vol. 90 No. 4 (August 15), 1997: pp. 1673-1683
© 1997 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Stem CellsHome page
P. D. Cravens, M. W. Melkus, A. Padgett-Thomas, M. Islas-Ohlmayer, M. del P. Martin, and J. V. Garcia
Development and Activation of Human Dendritic Cells In Vivo in a Xenograft Model of Human Hematopoiesis
Stem Cells, February 1, 2005; 23(2): 264 - 278.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
U. Deiters, M. Gumenscheimer, C. Galanos, and P. F. Muhlradt
Toll-Like Receptor 2- and 6-Mediated Stimulation by Macrophage-Activating Lipopeptide 2 Induces Lipopolysaccharide (LPS) Cross Tolerance in Mice, Which Results in Protection from Tumor Necrosis Factor Alpha but in Only Partial Protection from Lethal LPS Doses
Infect. Immun., August 1, 2003; 71(8): 4456 - 4462.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
A. S. Cross
Invited review: Endotoxin tolerance -- current concepts in historical perspective
Innate Immunity, April 1, 2002; 8(2): 83 - 98.
[PDF]


Home page
Infect. Immun.Home page
M. D. Lehner, J. Ittner, D. S. Bundschuh, N. van Rooijen, A. Wendel, and T. Hartung
Improved Innate Immunity of Endotoxin-Tolerant Mice Increases Resistance to Salmonella enterica Serovar Typhimurium Infection despite Attenuated Cytokine Response
Infect. Immun., January 1, 2001; 69(1): 463 - 471.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
N. Rayhane, C. Fitting, and J.-M. Cavaillon
Dissociation of IFN-{gamma} from IL-12 and IL-18 production during endotoxin tolerance
Innate Immunity, October 1, 1999; 5(5-6): 319 - 324.
[Abstract] [PDF]


Home page
Infect. Immun.Home page
S. Kanangat, G. U. Meduri, E. A. Tolley, D. R. Patterson, C. U. Meduri, C. Pak, J. P. Griffin, M. S. Bronze, and D. R. Schaberg
Effects of Cytokines and Endotoxin on the Intracellular Growth of Bacteria
Infect. Immun., June 1, 1999; 67(6): 2834 - 2840.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020